WuXi XDC Cayman Inc. (HKG:2268)
Hong Kong · Delayed Price · Currency is HKD 60.30
+1.40 (2.38%)
Jul 29, 2025, 9:45 AM HKT
WuXi XDC Cayman Company Description
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates.
It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China.
WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
WuXi XDC Cayman Inc.
| Country | Cayman Islands |
| Founded | 2013 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,041 |
| CEO | Jincai Li |
Contact Details
Address: No. 11 Xinhui Ring Road Wuxi China | |
| Website | wuxixdc.com |
Stock Details
| Ticker Symbol | 2268 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG9808A1058 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jincai Li Ph.D. | Chief Executive Officer and Executive Director |
| Xiaojie Xi | Company Secretary, Chief Financial Officer and Executive Director |
| Jingwei Zhang | Chief Operating Officer and Executive Director |
| Dr. Meiying Zhu | Chief Technology Officer |
| Dr. Jianjun Luo | Vice President |